Nektar Therapeutics NKTR
Set alert
38.87 USD -0.31 -0.79%
At close · Oct 30
38.50 -0.37 -0.95%
After hours · Oct 30, 5:19 PM ET
38.00 Day range 39.30
35.12 52-week range 100.35
- YTD
- -8.07%
- 1 year
- -38.11%
- Open
- 38.92
- Prev close
- 39.18
- Mkt cap
- 1.33B
- Vol
- 600.97K
- Avg vol
- 1.10M
- EPS
- -18.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 38.00
- High
- 39.30
- Forward P/E
- -3.77
- Beta
- 1.27
- Short ratio
- 3.62
- Inst. own
- 107.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 56.40
- 200-d avg
- 64.99
- 1y target
- 133.08
2Y chart
Events in this range
- Jun 9, 2025Split: 1 for 15
- Aug 7, 2025Earnings: -2.95; estimate -3.02756; surprise 2.56%
- Nov 6, 2025Earnings: -1.85; estimate -2.85; surprise 35.09%
- Mar 12, 2026Earnings: -1.78; estimate -2.47411; surprise 28.05%
- May 7, 2026Earnings: -1.82; estimate -1.58235; surprise -15.02%
- Aug 13, 2026Earnings: -1.23; estimate -1.97; surprise 37.56%
- Sep 28, 2026Rating: BTIG · Buy → Buy
- Oct 2, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 9, 2026Rating: Raymond James · — → Market Perform
- Oct 9, 2026Rating: BTIG · Buy → Buy
- Oct 12, 2026Rating: Leerink Partners · — → Outperform
- Oct 12, 2026Rating: UBS · — → Neutral
Signals (90)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | May 26, 2026 | 5 months ago |
| RSI: Oversold | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| RSI: Overbought | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 10, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 10, 2026 | 8 months ago |
| RSI: Overbought | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| SMA: Bullish | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| RSI: Oversold | Jan 13, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 9, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| RSI: Overbought | Oct 2, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 30, 2025 | 1 year ago |
| RSI: Overbought | Sep 26, 2025 | 1 year ago |
| RSI: Overbought | Sep 4, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 14, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| RSI: Overbought | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 11, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bearish | Jun 5, 2025 | 1 year ago |
| SMA: Bullish | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 14, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| RSI: Oversold | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.33B
- Enterprise value
- 789.32M
- Trailing P/E
- 0.00
- Forward P/E
- -3.77
- PEG ratio
- 0.31
- Price / sales
- 24.31
- Price / book
- 1.47
- EPS (TTM)
- -18.96
- Beta
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -287.84%
- Revenue (TTM)
- 54.59M
- Revenue growth
- -9.30%
- Free cash flow
- -134.77M
- Total cash
- 684.34M
- Total debt
- 135.93M
- Return on equity
- -35.76%
- Shares outstanding
- 34.14M
- Short % of float
- 22.59%
- 50-day average
- 56.40
- 200-day average
- 64.99
Analyst view
Consensus: buy
Buy
Price target (mean) 133.08 +242.4% upside
Now 38.87
- Target (low)
- 50.00
- Target (mean)
- 133.08
- Target (high)
- 192.00
Ratings (0m) 15 11 buy · 4 hold · 0 sell
- Strong buy1
- Buy10
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -2.11.
Financials — quick view
NKTR Revenue — quarterly 10.13M
NKTR Net income — quarterly -40.62M
NKTR EPS — quarterly -1.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -2.07 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -1.97 | -1.23 | +0.74 | +37.56% |
| May 7, 2026 | Mar 31, 2026 | -1.58 | -1.82 | -0.24 | -15.02% |
| Mar 12, 2026 | Dec 31, 2025 | -2.47 | -1.78 | +0.69 | +28.05% |
| Nov 6, 2025 | Sep 30, 2025 | -2.85 | -1.85 | +1.00 | +35.09% |
| Aug 7, 2025 | Jun 30, 2025 | -3.03 | -2.95 | +0.08 | +2.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Neutral |
| Oct 12, 2026 | Leerink Partners | init | — | Outperform |
| Oct 9, 2026 | BTIG | reit | Buy | Buy |
| Oct 9, 2026 | Raymond James | init | — | Market Perform |
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 28, 2026 | BTIG | reit | Buy | Buy |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nektar.com
News
- Nektar Therapeutics: Focus Returns To The Strengths Of The Company
- Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
- Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysis
- Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
- UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
- Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
- BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
- Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating
Your note
Sign in to keep a note on NKTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ROBIN HOWARD W | Chief Executive Officer | Sale | Aug 17, 2026 | 54,655 |
| WILSON MARK ANDREW | Officer | Sale | Nov 24, 2025 | 21,585 |
| ZALEVSKY JONATHAN | Officer | Sale | Aug 17, 2026 | 9,570 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.84% | 5,067,920 | 196.99M | Jun 29, 2026 |
| Two Seas Capital Lp | 9.80% | 3,345,978 | 130.06M | Sep 29, 2026 |
| Blackrock Inc. | 8.62% | 2,941,851 | 114.35M | Jun 29, 2026 |
| BVF Inc. | 7.00% | 2,391,075 | 92.94M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.38% | 1,496,849 | 58.18M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.52% | 1,202,004 | 46.72M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.42% | 1,850,478 | 71.93M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 1,075,108 | 41.79M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.86% | 975,224 | 37.91M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.61% | 892,637 | 34.70M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.47% | 500,351 | 19.45M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.24% | 424,554 | 16.50M | Aug 30, 2026 |